Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Assets (2016 - 2026)

Zevra Therapeutics filings provide 12 years of Non-Current Assets readings, the most recent being $61.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 12244.8% to $61.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $228.8 million, a 45654.8% increase, with the full-year FY2025 number at $61.7 million, up 12244.8% from a year prior.
  • Non-Current Assets hit $61.7 million in Q4 2025 for Zevra Therapeutics, up from $45.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $139.0 million in Q3 2023 to a low of -$106.2 million in Q1 2022.
  • Median Non-Current Assets over the past 5 years was $15.1 million (2021), compared with a mean of $23.1 million.
  • Biggest five-year swings in Non-Current Assets: crashed 4024.83% in 2022 and later soared 12244.8% in 2025.
  • Zevra Therapeutics' Non-Current Assets stood at $17.9 million in 2021, then grew by 25.84% to $22.5 million in 2022, then crashed by 51.57% to $10.9 million in 2023, then plummeted by 95.41% to $500000.0 in 2024, then soared by 12244.8% to $61.7 million in 2025.
  • The last three reported values for Non-Current Assets were $61.7 million (Q4 2025), $45.0 million (Q3 2025), and $29.9 million (Q2 2025) per Business Quant data.